搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按时间排序
按相关度排序
22 小时
BYU股价触及52周低点0.23美元,面临市场挑战
在动荡的市场环境中,BYU股价已跌至52周低点,仅达到0.23美元的价格水平。这一显著下跌反映了该公司的一个更广泛趋势,过去一年其价值已大幅缩水。投资者目睹了该股票价值一年内惊人的变化,China Commercial经历了高达-94.83%的急剧下降。这一急剧下跌凸显了该公司在竞争激烈且快速变化的经济环境中面临的挑战,使市场观察者密切关注BYU的表现,寻找稳定或进一步下跌的迹象。 在其他近期新闻 ...
5 天
PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug
European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data ...
FiercePharma
5 天
Fierce Pharma Asia—Lilly's China expansions; Gilead's scrapped MASH deal; Leqembi's vial ...
Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...
PipelineReview.com
5 天
Chengdu Baiyu enters into a license agreement for the development and commercialization of ...
CHENGDU, China I October16, 2024 I Chengdu Baiyu Pharmaceutical Co., Ltd. ("Baiyu") today announced that it has entered into an exclusive license ...
The Pharma Letter
6 天
Chengdu Baiyu enters into a license deal with Novartis
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma ...
FierceBiotech
6 天
Novartis pays China's Baiyu $70M upfront, with $1.1B chaser, for small molecule cancer ...
Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...
ENDPOINTS NEWS
6 天
Novartis pays $70M upfront to license Chinese biotech’s antitumor drug
Novartis is spending $70 million upfront on a small molecule antitumor drug from the Chinese biotech Chengdu Baiyu. The Swiss ...
The Pharma Letter
6 天
FDA guidance for reconsideration at the division level under GDUFA
The US Food and Drug Administration (FDA) yesterday published the guidance for industry, “Requests for Reconsideration at the ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈